Adam Crystal, M.D., Ph.D. joined C4 Therapeutics in February 2019 as our Chief Medical Officer. Previously, Adam was at Novartis Institutes for Biomedical Research, most recently as Senior Director, where he led several early clinical development programs. Before transitioning to industry, Adam was a medical oncologist at Massachusetts General Hospital where he researched resistance mechanisms to targeted therapies. Adam was also a laboratory-based researcher at Massachusetts General Hospital where his work on resistance mechanisms to targeted therapies was recognized with the American Society of Clinical Oncology Conquer Cancer Young Investigator Award and was also published in Science. He trained at Massachusetts General Hospital in internal medicine, and in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute. Adam holds an M.D., as well as a Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine.

Stew Fisher, Ph.D. joined C4 Therapeutics in May 2016 and has served as our Chief Scientific Officer since May 2018. Between May 2016 and May 2018, Stew served as our Senior Director of Discovery Sciences. Prior to joining C4 Therapeutics, Stew held senior leadership roles at the Broad Institute, including Director of Quantitative of Biochemistry and Enzymology, where he developed and implemented biochemical plans for therapeutic projects. He previously spent fifteen years at AstraZeneca in roles of increasing responsibility across target validation, drug discovery and clinical candidate support, including Executive Director of Infection Bioscience. Stew started his career at Hoffmann-La Roche as a Research Scientist after completing an NIH Post-Doctoral Fellowship at Harvard Medical School. Stew holds a Ph.D. in Organic Chemistry from the California Institute of Technology, and a B.A. in Chemistry from the University of Vermont.